Verismo Therapeutics, a clinical-stage CAR T company and pioneer of the novel KIR-CAR platform technology, announced that it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110, an investigational new drug administered intravenously for the treatment of mesothelin-expressing mesothelioma, cholangiocarcinoma, and ovarian cancer.
AstraZeneca, a global pharmaceutical company, announced that Imfinzi (durvalumab), a human monoclonal antibody that binds to the PD-L1 protein, had been approved in the U.S. by the FDA for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5383
Published Date: Nov 20, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing Research & development and rising awareness about cholangiocarcinoma are the major factors driving the growth of the cholangiocarcinoma market.
The market size of cholangiocarcinoma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2024-2036.
The major players in the market are Eli Lilly and Company, AstraZeneca, Merck Sharp & Dohme Corp, Basilea Pharmaceutica, Incyte Corporation, Agios Pharmaceuticals, Specialised Therapeutics, PlantPraxis Biotecnologia, Dr. Reddyâ€™s Laboratories, and others.
The retail pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.